{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "04",
                "@timestamp": "2022-06-04T13:53:40.000040-04:00",
                "@year": "2022",
                "@month": "06"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2021",
                "@month": "12"
            }
        },
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "125374400",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "MedPark Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "125374400",
                                "@dptid": "127634335"
                            },
                            "@affiliation-instance-id": "2017898532-e7c266575e41da840e90d617aef56e59",
                            "ce:source-text": "Department of Medical Oncology, MedPark Hospital, Bangkok, Thailand",
                            "@dptid": "127634335"
                        },
                        "author": [
                            {
                                "ce:given-name": "Sudpreeda",
                                "preferred-name": {
                                    "ce:given-name": "Sudpreeda",
                                    "ce:initials": "S.",
                                    "ce:surname": "Chainitikun",
                                    "ce:indexed-name": "Chainitikun S."
                                },
                                "@author-instance-id": "2017898532-ff4362467a89f40d1b3a757ee050a30d",
                                "@seq": "1",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Chainitikun",
                                "@auid": "57218292180",
                                "ce:indexed-name": "Chainitikun S."
                            },
                            {
                                "ce:given-name": "Siyamol",
                                "preferred-name": {
                                    "ce:given-name": "Siyamol",
                                    "ce:initials": "S.",
                                    "ce:surname": "Mingmalairak",
                                    "ce:indexed-name": "Mingmalairak S."
                                },
                                "@author-instance-id": "2017898532-6a3bb98993a48a542ed53f61518cee7f",
                                "@seq": "2",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Mingmalairak",
                                "@auid": "57190171759",
                                "ce:indexed-name": "Mingmalairak S."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60022183",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "King Chulalongkorn Memorial Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60022183",
                                "@dptid": "122312150"
                            },
                            "@affiliation-instance-id": "2017898532-045b7c43bb8b1c29390376821eb01f99",
                            "ce:source-text": "Department of Medical Oncology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand",
                            "@dptid": "122312150"
                        },
                        "author": [{
                            "ce:given-name": "Napa",
                            "preferred-name": {
                                "ce:given-name": "Napa",
                                "ce:initials": "N.",
                                "ce:surname": "Parinyanitikul",
                                "ce:indexed-name": "Parinyanitikul N."
                            },
                            "@author-instance-id": "2017898532-4484046faa0cb8f90d2290d82b06fd20",
                            "@seq": "3",
                            "ce:initials": "N.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Parinyanitikul",
                            "@auid": "36554719100",
                            "ce:indexed-name": "Parinyanitikul N."
                        }]
                    }
                ],
                "citation-title": "What is the best systemic treatment for newly diagnosed inflammatory breast cancer?-a narrative review",
                "abstracts": "Â© 2021 AME Publishing Company. All rights reserved.Objective: The propose of this review to discuss of the systemic treatment options for newly diagnosed inflammatory breast cancer (IBC) including the recent data of immune checkpoint inhibitor, CDK4/6 inhibitor and anti-HER2 therapy. Aim to provide a pragmatic treatment in a gray area or concerning issues of real-world practice. Background: IBC is a rare and aggressive disease. Upfront systemic treatment followed by surgery and radiation therapy or \"Tri-modality\" treatment is a standard of care for newly diagnosed IBC. Due to its rarity, the data of systemic treatment for IBC has been extrapolated mostly from non-IBC clinical trials. Methods: We summarized the recent data of systemic treatment stratified by concerning topics and breast cancer subtypes. Some topics are less likely to have strong data from IBC clinical trial to supports. Therefore, we interpolate the non-IBC data to support our review. Conclusions: IBC is challenging in the clinical management. The development of novel systemic treatment is urgently needed, especially for IBC-specific clinical trials.",
                "correspondence": {
                    "affiliation": {
                        "country": "Thailand",
                        "address-part": "3333 Rama IV Rd., Khwaeng Khlong Toei, Khet Khlong Toei",
                        "postal-code": "10110",
                        "@country": "tha",
                        "city": "Bangkok",
                        "organization": [
                            {"$": "Department of Medical Oncology"},
                            {"$": "Light of Day Center"},
                            {"$": "MedPark Hospital"}
                        ],
                        "ce:source-text": "Department of Medical Oncology, Light of Day Center, MedPark Hospital, 3333 Rama IV Rd., Khwaeng Khlong Toei, Khet Khlong Toei, Bangkok 10110, Thailand"
                    },
                    "person": {
                        "ce:given-name": "Sudpreeda",
                        "ce:initials": "S.",
                        "ce:surname": "Chainitikun",
                        "ce:indexed-name": "Chainitikun S."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "anti-HER2 therapy",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "CDK4/6 inhibitor",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "immunotherapy",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Inflammatory breast cancer (IBC)",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "re"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://cco.amegroups.com/article/view/81427/html",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {"@xml:lang": "eng"},
                    "volisspag": {"voliss": {
                        "@volume": "10",
                        "@issue": "6"
                    }},
                    "@type": "j",
                    "sourcetitle": "Chinese Clinical Oncology",
                    "publicationdate": {
                        "month": "12",
                        "year": "2021",
                        "date-text": "December 2021",
                        "day": "01"
                    },
                    "sourcetitle-abbrev": "Chin. Clin. Oncol.",
                    "@country": "hkg",
                    "issn": [
                        {
                            "$": "23043873",
                            "@type": "electronic"
                        },
                        {
                            "$": "23043865",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2021"},
                    "publisher": {"publishername": "AME Publishing Company"},
                    "article-number": "81427",
                    "@srcid": "21100448930"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "26",
                                    "classification-description": "Immunology, Serology and Transplantation"
                                },
                                {
                                    "classification-code": "29",
                                    "classification-description": "Clinical and Experimental Biochemistry"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2730"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "147014-97-9",
                                    "chemical-name": "cyclin dependent kinase 4"
                                },
                                {
                                    "cas-registry-number": "137632-09-8",
                                    "chemical-name": "epidermal growth factor receptor 2"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": {"chemical-name": "Receptor, ErbB-2"}
                        }
                    ]}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2022 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "NURSNG"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "SNEMB"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "01",
                    "@timestamp": "BST 12:30:58",
                    "@year": "2022",
                    "@month": "06"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2017898532",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "636545975",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "940076988",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20220407444",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "34670376",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "2022192350",
                            "@idtype": "NURSNG"
                        },
                        {
                            "$": "20221426165",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20221570449",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "2022066974",
                            "@idtype": "SNEMB"
                        },
                        {
                            "$": "20229008862807",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85123646568",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85123646568",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "636545975",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "643108427",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.21037/cco-21-81"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "38",
                "reference": [
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "van Uden DJP, van Maaren MC, Strobbe LJA, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res 2019;21:113.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85073594992",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "21"},
                                "pagerange": {"@first": "113"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "DJP",
                                        "@_fa": "true",
                                        "ce:surname": "van Uden",
                                        "ce:indexed-name": "van Uden DJP"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "MC",
                                        "@_fa": "true",
                                        "ce:surname": "van Maaren",
                                        "ce:indexed-name": "van Maaren MC"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "LJA",
                                        "@_fa": "true",
                                        "ce:surname": "Strobbe",
                                        "ce:indexed-name": "Strobbe LJA"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res"
                        },
                        "ce:source-text": "van Uden DJP, van Maaren MC, Strobbe LJA, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res 2019;21:113."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Fouad TM, Kogawa T, Liu DD, et al. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 2015;152:407-16.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84946489232",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "152"},
                                "pagerange": {
                                    "@first": "407",
                                    "@last": "416"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "TM",
                                        "@_fa": "true",
                                        "ce:surname": "Fouad",
                                        "ce:indexed-name": "Fouad TM"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Kogawa",
                                        "ce:indexed-name": "Kogawa T"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "DD",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu DD"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Fouad TM, Kogawa T, Liu DD, et al. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 2015;152:407-16."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 2011;117:1819-26.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "79955439847",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "117"},
                                "pagerange": {
                                    "@first": "1819",
                                    "@last": "1826"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Dawood",
                                        "ce:indexed-name": "Dawood S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "NT",
                                        "@_fa": "true",
                                        "ce:surname": "Ueno",
                                        "ce:indexed-name": "Ueno NT"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V",
                                        "@_fa": "true",
                                        "ce:surname": "Valero",
                                        "ce:indexed-name": "Valero V"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 2011;117:1819-26."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-74.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2004"},
                            "ref-title": {"ref-titletext": "Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "7044272570",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "4067",
                                    "@last": "4074"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JA",
                                        "@_fa": "true",
                                        "ce:surname": "Low",
                                        "ce:indexed-name": "Low JA"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AW",
                                        "@_fa": "true",
                                        "ce:surname": "Berman",
                                        "ce:indexed-name": "Berman AW"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "SM",
                                        "@_fa": "true",
                                        "ce:surname": "Steinberg",
                                        "ce:indexed-name": "Steinberg SM"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-74."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol 2018;25:1783-5.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85045692461",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "25"},
                                "pagerange": {
                                    "@first": "1783",
                                    "@last": "1785"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "AE",
                                    "@_fa": "true",
                                    "ce:surname": "Giuliano",
                                    "ce:indexed-name": "Giuliano AE"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "SB",
                                    "@_fa": "true",
                                    "ce:surname": "Edge",
                                    "ce:indexed-name": "Edge SB"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "GN.",
                                    "@_fa": "true",
                                    "ce:surname": "Hortobagyi",
                                    "ce:indexed-name": "Hortobagyi GN."
                                }
                            ]},
                            "ref-sourcetitle": "Ann Surg Oncol"
                        },
                        "ce:source-text": "Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol 2018;25:1783-5."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Hester RH, Hortobagyi GN, Lim B. Inflammatory breast cancer: early recognition and diagnosis is critical. Am J Obstet Gynecol 2021;225:392-6.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Inflammatory breast cancer: early recognition and diagnosis is critical"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85107757933",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "225"},
                                "pagerange": {
                                    "@first": "392",
                                    "@last": "396"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "RH",
                                    "@_fa": "true",
                                    "ce:surname": "Hester",
                                    "ce:indexed-name": "Hester RH"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "GN",
                                    "@_fa": "true",
                                    "ce:surname": "Hortobagyi",
                                    "ce:indexed-name": "Hortobagyi GN"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Lim",
                                    "ce:indexed-name": "Lim B."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Obstet Gynecol"
                        },
                        "ce:source-text": "Hester RH, Hortobagyi GN, Lim B. Inflammatory breast cancer: early recognition and diagnosis is critical. Am J Obstet Gynecol 2021;225:392-6."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer 1995;62:382-5.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1995"},
                            "ref-title": {"ref-titletext": "Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?"},
                            "refd-itemidlist": {"itemid": {
                                "$": "0029083919",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "62"},
                                "pagerange": {
                                    "@first": "382",
                                    "@last": "385"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Bonnier",
                                        "ce:indexed-name": "Bonnier P"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Charpin",
                                        "ce:indexed-name": "Charpin C"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Lejeune",
                                        "ce:indexed-name": "Lejeune C"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Int J Cancer"
                        },
                        "ce:source-text": "Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer 1995;62:382-5."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002;8:3857-62.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2002"},
                            "ref-title": {"ref-titletext": "Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "0036899982",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {
                                    "@first": "3857",
                                    "@last": "3862"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "NJ",
                                        "@_fa": "true",
                                        "ce:surname": "McCarthy",
                                        "ce:indexed-name": "McCarthy NJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X",
                                        "@_fa": "true",
                                        "ce:surname": "Yang",
                                        "ce:indexed-name": "Yang X"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "IR",
                                        "@_fa": "true",
                                        "ce:surname": "Linnoila",
                                        "ce:indexed-name": "Linnoila IR"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002;8:3857-62."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Lim B, Woodward WA, Wang X, et al. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer 2018;18:485-99.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Inflammatory breast cancer biology: the tumour microenvironment is key"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85046031156",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "18"},
                                "pagerange": {
                                    "@first": "485",
                                    "@last": "499"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B",
                                        "@_fa": "true",
                                        "ce:surname": "Lim",
                                        "ce:indexed-name": "Lim B"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "WA",
                                        "@_fa": "true",
                                        "ce:surname": "Woodward",
                                        "ce:indexed-name": "Woodward WA"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang X"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Rev Cancer"
                        },
                        "ce:source-text": "Lim B, Woodward WA, Wang X, et al. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer 2018;18:485-99."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Dobiasova B, Mego M. Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility. Breast Cancer (Dove Med Press) 2020;12:153-63.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85094107926",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {
                                    "@first": "153",
                                    "@last": "163"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "B",
                                    "@_fa": "true",
                                    "ce:surname": "Dobiasova",
                                    "ce:indexed-name": "Dobiasova B"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Mego",
                                    "ce:indexed-name": "Mego M."
                                }
                            ]},
                            "ref-sourcetitle": "Breast Cancer (Dove Med Press)"
                        },
                        "ce:source-text": "Dobiasova B, Mego M. Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility. Breast Cancer (Dove Med Press) 2020;12:153-63."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Ross JS, Ali SM, Wang K, et al. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat 2015;154:155-62.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84945494649",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "154"},
                                "pagerange": {
                                    "@first": "155",
                                    "@last": "162"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JS",
                                        "@_fa": "true",
                                        "ce:surname": "Ross",
                                        "ce:indexed-name": "Ross JS"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "SM",
                                        "@_fa": "true",
                                        "ce:surname": "Ali",
                                        "ce:indexed-name": "Ali SM"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang K"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Ross JS, Ali SM, Wang K, et al. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat 2015;154:155-62."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Liang X, Vacher S, Boulai A, et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Res 2018;20:88.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85054931877",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {"@first": "88"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X",
                                        "@_fa": "true",
                                        "ce:surname": "Liang",
                                        "ce:indexed-name": "Liang X"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Vacher",
                                        "ce:indexed-name": "Vacher S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Boulai",
                                        "ce:indexed-name": "Boulai A"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res"
                        },
                        "ce:source-text": "Liang X, Vacher S, Boulai A, et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Res 2018;20:88."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Matsuda N, Lim B, Wang Y, et al. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat 2017;163:263-72.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Identification of frequent somatic mutations in inflammatory breast cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85014038164",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "163"},
                                "pagerange": {
                                    "@first": "263",
                                    "@last": "272"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Matsuda",
                                        "ce:indexed-name": "Matsuda N"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B",
                                        "@_fa": "true",
                                        "ce:surname": "Lim",
                                        "ce:indexed-name": "Lim B"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang Y"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Matsuda N, Lim B, Wang Y, et al. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat 2017;163:263-72."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Ueno NT, Espinosa Fernandez JR, Cristofanilli M, et al. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer 2018;9:1437-47.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85045246520",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {
                                    "@first": "1437",
                                    "@last": "1447"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "NT",
                                        "@_fa": "true",
                                        "ce:surname": "Ueno",
                                        "ce:indexed-name": "Ueno NT"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "JR",
                                        "@_fa": "true",
                                        "ce:surname": "Espinosa Fernandez",
                                        "ce:indexed-name": "Espinosa Fernandez JR"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Cristofanilli",
                                        "ce:indexed-name": "Cristofanilli M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Cancer"
                        },
                        "ce:source-text": "Ueno NT, Espinosa Fernandez JR, Cristofanilli M, et al. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer 2018;9:1437-47."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory Breast Cancer: A Literature Review. World J Oncol 2018;9:129-35.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Inflammatory Breast Cancer: A Literature Review"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85077703516",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {
                                    "@first": "129",
                                    "@last": "135"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Mamouch",
                                        "ce:indexed-name": "Mamouch F"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Berrada",
                                        "ce:indexed-name": "Berrada N"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Z",
                                        "@_fa": "true",
                                        "ce:surname": "Aoullay",
                                        "ce:indexed-name": "Aoullay Z"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "World J Oncol"
                        },
                        "ce:source-text": "Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory Breast Cancer: A Literature Review. World J Oncol 2018;9:129-35."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020;38:3987-98.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85095442532",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "3987",
                                    "@last": "3998"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "SRD",
                                        "@_fa": "true",
                                        "ce:surname": "Johnston",
                                        "ce:indexed-name": "Johnston SRD"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Harbeck",
                                        "ce:indexed-name": "Harbeck N"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Hegg",
                                        "ce:indexed-name": "Hegg R"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020;38:3987-98."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2021;22:212-22.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85099906928",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "212",
                                    "@last": "222"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "EL",
                                        "@_fa": "true",
                                        "ce:surname": "Mayer",
                                        "ce:indexed-name": "Mayer EL"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AC",
                                        "@_fa": "true",
                                        "ce:surname": "Dueck",
                                        "ce:indexed-name": "Dueck AC"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2021;22:212-22."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Loibl S, MarmÃ© F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol 2021;39:1518-30.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85104974124",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "39"},
                                "pagerange": {
                                    "@first": "1518",
                                    "@last": "1530"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Loibl",
                                        "ce:indexed-name": "Loibl S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "MarmÃ©",
                                        "ce:indexed-name": "Marme F"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Loibl S, MarmÃ© F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol 2021;39:1518-30."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Slamon DJ, Fasching PA, Patel R, et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). J Clin Oncol 2019;37:abstr TPS597.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85109556413",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {"@volume": "37"}},
                            "ref-text": "abstr TPS597",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "DJ",
                                        "@_fa": "true",
                                        "ce:surname": "Slamon",
                                        "ce:indexed-name": "Slamon DJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "PA",
                                        "@_fa": "true",
                                        "ce:surname": "Fasching",
                                        "ce:indexed-name": "Fasching PA"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Patel",
                                        "ce:indexed-name": "Patel R"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Slamon DJ, Fasching PA, Patel R, et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). J Clin Oncol 2019;37:abstr TPS597."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020;382:810-21.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Pembrolizumab for Early Triple-Negative Breast Cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85080089288",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "382"},
                                "pagerange": {
                                    "@first": "810",
                                    "@last": "821"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Schmid",
                                        "ce:indexed-name": "Schmid P"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Cortes",
                                        "ce:indexed-name": "Cortes J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L",
                                        "@_fa": "true",
                                        "ce:surname": "Pusztai",
                                        "ce:indexed-name": "Pusztai L"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020;382:810-21."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Nanda R, Liu MC, Yau C, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol 2020;6:676-84.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082879839",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "6"},
                                "pagerange": {
                                    "@first": "676",
                                    "@last": "684"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Nanda",
                                        "ce:indexed-name": "Nanda R"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "MC",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu MC"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Yau",
                                        "ce:indexed-name": "Yau C"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Nanda R, Liu MC, Yau C, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol 2020;6:676-84."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 2020;396:1090-100.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85091795852",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "396"},
                                "pagerange": {
                                    "@first": "1090",
                                    "@last": "1100"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "EA",
                                        "@_fa": "true",
                                        "ce:surname": "Mittendorf",
                                        "ce:indexed-name": "Mittendorf EA"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang H"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "CH",
                                        "@_fa": "true",
                                        "ce:surname": "Barrios",
                                        "ce:indexed-name": "Barrios CH"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 2020;396:1090-100."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 2021;39:abstr 506.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85114495175",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {"@volume": "39"}},
                            "ref-text": "abstr 506",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Loibl",
                                        "ce:indexed-name": "Loibl S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Schneeweiss",
                                        "ce:indexed-name": "Schneeweiss A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "JB",
                                        "@_fa": "true",
                                        "ce:surname": "Huober",
                                        "ce:indexed-name": "Huober JB"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 2021;39:abstr 506."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:44-59.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85077157414",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "21"},
                                "pagerange": {
                                    "@first": "44",
                                    "@last": "59"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Schmid",
                                        "ce:indexed-name": "Schmid P"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "HS",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo HS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Adams",
                                        "ce:indexed-name": "Adams S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:44-59."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379:2108-21.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85056176186",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "379"},
                                "pagerange": {
                                    "@first": "2108",
                                    "@last": "2121"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Schmid",
                                        "ce:indexed-name": "Schmid P"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Adams",
                                        "ce:indexed-name": "Adams S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "HS",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo HS"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379:2108-21."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Bertucci F, Finetti P, Colpaert C, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 2015;6:13506-19.",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84931073954",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "6"},
                                "pagerange": {
                                    "@first": "13506",
                                    "@last": "13519"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Bertucci",
                                        "ce:indexed-name": "Bertucci F"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Finetti",
                                        "ce:indexed-name": "Finetti P"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Colpaert",
                                        "ce:indexed-name": "Colpaert C"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Oncotarget"
                        },
                        "ce:source-text": "Bertucci F, Finetti P, Colpaert C, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 2015;6:13506-19."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Van Berckelaer C, Rypens C, van Dam P, et al. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Res 2019;21:28.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85061864019",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "21"},
                                "pagerange": {"@first": "28"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Van Berckelaer",
                                        "ce:indexed-name": "Van Berckelaer C"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Rypens",
                                        "ce:indexed-name": "Rypens C"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "van Dam",
                                        "ce:indexed-name": "van Dam P"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res"
                        },
                        "ce:source-text": "Van Berckelaer C, Rypens C, van Dam P, et al. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Res 2019;21:28."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Arias-Pulido H, Cimino-Mathews A, Chaher N, et al. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat 2018;171:273-82.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85047934012",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "171"},
                                "pagerange": {
                                    "@first": "273",
                                    "@last": "282"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Arias-Pulido",
                                        "ce:indexed-name": "Arias-Pulido H"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Cimino-Mathews",
                                        "ce:indexed-name": "Cimino-Mathews A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Chaher",
                                        "ce:indexed-name": "Chaher N"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Arias-Pulido H, Cimino-Mathews A, Chaher N, et al. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat 2018;171:273-82."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Chainitikun S, Saleem S, Lim B, et al. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 2020;29:1-12.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Update on systemic treatment for newly diagnosed inflammatory breast cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85091826977",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "29"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "12"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Chainitikun",
                                        "ce:indexed-name": "Chainitikun S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Saleem",
                                        "ce:indexed-name": "Saleem S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B",
                                        "@_fa": "true",
                                        "ce:surname": "Lim",
                                        "ce:indexed-name": "Lim B"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Adv Res"
                        },
                        "ce:source-text": "Chainitikun S, Saleem S, Lim B, et al. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 2020;29:1-12."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278-84.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84883359410",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "24"},
                                "pagerange": {
                                    "@first": "2278",
                                    "@last": "2284"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Schneeweiss",
                                        "ce:indexed-name": "Schneeweiss A"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Chia",
                                        "ce:indexed-name": "Chia S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Hickish",
                                        "ce:indexed-name": "Hickish T"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278-84."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2018;89:27-35.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85037631693",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "89"},
                                "pagerange": {
                                    "@first": "27",
                                    "@last": "35"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Schneeweiss",
                                        "ce:indexed-name": "Schneeweiss A"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Chia",
                                        "ce:indexed-name": "Chia S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Hickish",
                                        "ce:indexed-name": "Hickish T"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2018;89:27-35."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2018;29:646-53.",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85046104301",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "29"},
                                "pagerange": {
                                    "@first": "646",
                                    "@last": "653"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "SM",
                                        "@_fa": "true",
                                        "ce:surname": "Swain",
                                        "ce:indexed-name": "Swain SM"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "MS",
                                        "@_fa": "true",
                                        "ce:surname": "Ewer",
                                        "ce:indexed-name": "Ewer MS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "Viale",
                                        "ce:indexed-name": "Viale G"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2018;29:646-53."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19:1630-40.",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85059318947",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "19"},
                                "pagerange": {
                                    "@first": "1630",
                                    "@last": "1640"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "MS",
                                        "@_fa": "true",
                                        "ce:surname": "van Ramshorst",
                                        "ce:indexed-name": "van Ramshorst MS"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "van der Voort",
                                        "ce:indexed-name": "van der Voort A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "ED",
                                        "@_fa": "true",
                                        "ce:surname": "van Werkhoven",
                                        "ce:indexed-name": "van Werkhoven ED"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19:1630-40."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Overmoyer B, Regan M, Hu J, et al. Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer. Cancer Res 2018;78:abstr P6-15-11.",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85129546209",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {"@volume": "78"}},
                            "ref-text": "abstr P6-15-11",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B",
                                        "@_fa": "true",
                                        "ce:surname": "Overmoyer",
                                        "ce:indexed-name": "Overmoyer B"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Regan",
                                        "ce:indexed-name": "Regan M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Hu",
                                        "ce:indexed-name": "Hu J"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Res"
                        },
                        "ce:source-text": "Overmoyer B, Regan M, Hu J, et al. Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer. Cancer Res 2018;78:abstr P6-15-11."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2018;19:115-26.",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85035092440",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "19"},
                                "pagerange": {
                                    "@first": "115",
                                    "@last": "126"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "SA",
                                        "@_fa": "true",
                                        "ce:surname": "Hurvitz",
                                        "ce:indexed-name": "Hurvitz SA"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "WF",
                                        "@_fa": "true",
                                        "ce:surname": "Symmans",
                                        "ce:indexed-name": "Symmans WF"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2018;19:115-26."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "National Comprehensive Cancer Network. Breast Cancer (Version 4.2021). Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf",
                        "@id": "36",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85108098158",
                                "@idtype": "SGR"
                            }},
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "National Comprehensive Cancer Network",
                                "ce:indexed-name": "National Comprehensive Cancer Network"
                            }},
                            "ref-sourcetitle": "Breast Cancer (Version 4.2021)"
                        },
                        "ce:source-text": "National Comprehensive Cancer Network. Breast Cancer (Version 4.2021). Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-28.",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85059540229",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "380"},
                                "pagerange": {
                                    "@first": "617",
                                    "@last": "628"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "von Minckwitz",
                                        "ce:indexed-name": "von Minckwitz G"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "CS",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang CS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "MS",
                                        "@_fa": "true",
                                        "ce:surname": "Mano",
                                        "ce:indexed-name": "Mano MS"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-28."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017;377:122-31.",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85023170865",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "377"},
                                "pagerange": {
                                    "@first": "122",
                                    "@last": "131"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "von Minckwitz",
                                        "ce:indexed-name": "von Minckwitz G"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Procter",
                                        "ce:indexed-name": "Procter M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E",
                                        "@_fa": "true",
                                        "ce:surname": "de Azambuja",
                                        "ce:indexed-name": "de Azambuja E"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017;377:122-31."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "125374400",
            "affilname": "MedPark Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125374400",
            "affiliation-country": "Thailand"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85123646568",
        "dc:description": "Objective: The propose of this review to discuss of the systemic treatment options for newly diagnosed inflammatory breast cancer (IBC) including the recent data of immune checkpoint inhibitor, CDK4/6 inhibitor and anti-HER2 therapy. Aim to provide a pragmatic treatment in a gray area or concerning issues of real-world practice. Background: IBC is a rare and aggressive disease. Upfront systemic treatment followed by surgery and radiation therapy or \"Tri-modality\" treatment is a standard of care for newly diagnosed IBC. Due to its rarity, the data of systemic treatment for IBC has been extrapolated mostly from non-IBC clinical trials. Methods: We summarized the recent data of systemic treatment stratified by concerning topics and breast cancer subtypes. Some topics are less likely to have strong data from IBC clinical trial to supports. Therefore, we interpolate the non-IBC data to support our review. Conclusions: IBC is challenging in the clinical management. The development of novel systemic treatment is urgently needed, especially for IBC-specific clinical trials.",
        "pubmed-id": "34670376",
        "prism:coverDate": "2021-12-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85123646568",
        "dc:creator": {"author": [{
            "ce:given-name": "Sudpreeda",
            "preferred-name": {
                "ce:given-name": "Sudpreeda",
                "ce:initials": "S.",
                "ce:surname": "Chainitikun",
                "ce:indexed-name": "Chainitikun S."
            },
            "@seq": "1",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "125374400",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125374400"
            },
            "ce:surname": "Chainitikun",
            "@auid": "57218292180",
            "author-url": "https://api.elsevier.com/content/author/author_id/57218292180",
            "ce:indexed-name": "Chainitikun S."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85123646568"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123646568&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85123646568&origin=inward"
            }
        ],
        "source-id": "21100448930",
        "citedby-count": "2",
        "prism:volume": "10",
        "subtype": "re",
        "dc:title": "What is the best systemic treatment for newly diagnosed inflammatory breast cancer?-a narrative review",
        "openaccess": "1",
        "prism:issn": "23043873 23043865",
        "publishercopyright": "Â© 2021 AME Publishing Company. All rights reserved.",
        "article-number": "81427",
        "prism:issueIdentifier": "6",
        "subtypeDescription": "Review",
        "prism:publicationName": "Chinese Clinical Oncology",
        "openaccessFlag": "true",
        "prism:doi": "10.21037/cco-21-81",
        "dc:identifier": "SCOPUS_ID:85123646568",
        "dc:publisher": "AME Publishing Company"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Antineoplastic Combined Chemotherapy Protocols",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Immunotherapy",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Inflammatory Breast Neoplasms",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Neoadjuvant Therapy",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Receptor, ErbB-2",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "anti-HER2 therapy"
        },
        {
            "@_fa": "true",
            "$": "CDK4/6 inhibitor"
        },
        {
            "@_fa": "true",
            "$": "immunotherapy"
        },
        {
            "@_fa": "true",
            "$": "Inflammatory breast cancer (IBC)"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Oncology",
        "@code": "2730",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Sudpreeda",
            "preferred-name": {
                "ce:given-name": "Sudpreeda",
                "ce:initials": "S.",
                "ce:surname": "Chainitikun",
                "ce:indexed-name": "Chainitikun S."
            },
            "@seq": "1",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "125374400",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125374400"
            },
            "ce:surname": "Chainitikun",
            "@auid": "57218292180",
            "author-url": "https://api.elsevier.com/content/author/author_id/57218292180",
            "ce:indexed-name": "Chainitikun S."
        },
        {
            "ce:given-name": "Siyamol",
            "preferred-name": {
                "ce:given-name": "Siyamol",
                "ce:initials": "S.",
                "ce:surname": "Mingmalairak",
                "ce:indexed-name": "Mingmalairak S."
            },
            "@seq": "2",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "125374400",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125374400"
            },
            "ce:surname": "Mingmalairak",
            "@auid": "57190171759",
            "author-url": "https://api.elsevier.com/content/author/author_id/57190171759",
            "ce:indexed-name": "Mingmalairak S."
        },
        {
            "ce:given-name": "Napa",
            "preferred-name": {
                "ce:given-name": "Napa",
                "ce:initials": "N.",
                "ce:surname": "Parinyanitikul",
                "ce:indexed-name": "Parinyanitikul N."
            },
            "@seq": "3",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60022183",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
            },
            "ce:surname": "Parinyanitikul",
            "@auid": "36554719100",
            "author-url": "https://api.elsevier.com/content/author/author_id/36554719100",
            "ce:indexed-name": "Parinyanitikul N."
        }
    ]}
}}